Verastem's VS-7375 shows 93% CA19-9 reduction in PDAC; plans Phase 3 in 1H2027

Verastem, Inc.

93% (13/14) of heavily pretreated mPDAC patients at 900mg QD achieved >50% reduction in CA19-9; all remain on treatment.
VS-7375 900mg QD achieved target plasma levels with clear PK separation from 600mg; safety profile favorable with low-grade GI AEs attenuating after cycle 1.
Dose-dependent anti-tumor activity across PDAC, mCRC, and NSCLC; combination with cetuximab or Gem/NabP shows combinability without overlapping toxicities.
Intends to collaborate with Erasca (ERAS) to evaluate VS-7375 + ERAS-0015 in preclinical models; future clinical trial collaboration possible.
Key milestones: complete Phase 1/2 enrollment by June 2026; first patient in Phase 2 registration trials mid-2026; FDA meeting by end of 2026; Phase 3 start 1H2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.